Your browser doesn't support javascript.
loading
Cysteinylated Albumin as a Potential Biomarker for the Progression of Kidney Disease in Patients With Type 2 Diabetes.
Imafuku, Tadashi; Watanabe, Hiroshi; Oniki, Kentaro; Yoshida, Akira; Kato, Hiromasa; Nakano, Takehiro; Tokumaru, Kai; Fujita, Issei; Arimura, Nanaka; Maeda, Hitoshi; Sakamoto, Yuki; Kondo, Nozomi; Morita, Ayami; Saruwatari, Junji; Tanaka, Motoko; Matsushita, Kazutaka; Wada, Takashi; Fukagawa, Masafumi; Otagiri, Masaki; Fitzgerald, Michael L; Jinnouchi, Hideaki; Maruyama, Toru.
Afiliación
  • Imafuku T; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
  • Watanabe H; Lipid Metabolism Unit, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA.
  • Oniki K; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan hnabe@kumamoto-u.ac.jp tomaru@gpo.kumamoto-u.ac.jp.
  • Yoshida A; Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
  • Kato H; Diabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
  • Nakano T; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
  • Tokumaru K; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
  • Fujita I; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
  • Arimura N; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
  • Maeda H; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
  • Sakamoto Y; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
  • Kondo N; Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
  • Morita A; Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
  • Saruwatari J; Diabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
  • Tanaka M; Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
  • Matsushita K; Department of Nephrology, Akebono Clinic, Kumamoto, Japan.
  • Wada T; Department of Nephrology, Akebono Clinic, Kumamoto, Japan.
  • Fukagawa M; Department of Nephrology and Laboratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
  • Otagiri M; Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Kanagawa, Japan.
  • Fitzgerald ML; Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan.
  • Jinnouchi H; Lipid Metabolism Unit, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA.
  • Maruyama T; Diabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
Diabetes Care ; 44(6): e115-e117, 2021 06.
Article en En | MEDLINE | ID: mdl-33905348
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Nefropatías Diabéticas / Enfermedades Renales Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Diabetes Care Año: 2021 Tipo del documento: Article País de afiliación: Japón
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Nefropatías Diabéticas / Enfermedades Renales Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Diabetes Care Año: 2021 Tipo del documento: Article País de afiliación: Japón